Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Status:
Suspended
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab
in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable),
cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in
chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood
vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor
cells than nab-paclitaxel alone.